Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT05645510
Recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Not applicable · Canada · 1 site
Registry update: 11 May 2026
NCT05363111
Recruiting
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 30 Oct 2026
NCT05652335
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Phase 1 · Belgium, Spain, France, United Kingdom, Japan, Netherlands, United States · 29 sites
Registry update: 3 Nov 2026
NCT05521802
Recruiting
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · China · 1 site
Registry update: 24 Mar 2023
NCT05558319
Recruiting
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
Phase 3 · Spain · 68 sites
Registry update: 25 Jun 2026
NCT05623020
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, Switzerland, China, Czechia, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Israel, Italy, Japan, South Korea, Netherlands, New Zealand, Poland, Puerto Rico, Taiwan, United States · 186 sites
Registry update: 27 Oct 2026
NCT05092451
Recruiting
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1/2 · United States · 1 site
Registry update: 7 Aug 2026
NCT05552222
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Phase 3 · Austria, Australia, Belgium, Brazil, Canada, Switzerland, China, Czechia, Germany, Denmark, Spain, France, United Kingdom, Greece, Israel, Italy, Japan, South Korea, Netherlands, Norway, Poland, Portugal, Sweden, United States · 268 sites
Registry update: 3 Nov 2026
Conflicting statuses (updated in the registry within the last month)
NCT06340646
Recruiting
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Not applicable · United States · 1 site
Registry update: 14 Jul 2026
NCT05372354
Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · Canada, Spain, United Kingdom, Norway, United States · 17 sites
Registry update: 5 Sept 2025
Conflicting statuses (not updated in the registry for 14 months)
NCT05519085
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, Chile, China, Czechia, Germany, Spain, Finland, France, United Kingdom, Greece, Ireland, Israel, India, Italy, Japan, South Korea, New Zealand, Poland, Puerto Rico, Portugal, Romania, United States, South Africa · 266 sites
Registry update: 30 Oct 2026
NCT05618041
Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Not applicable · China · 1 site
Registry update: 24 Jun 2025
NCT06659276
Recruiting
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
Not applicable · Italy · 1 site
Registry update: 26 Oct 2024
NCT05334069
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Not applicable · United States · 751 sites
Registry update: 4 Nov 2026
NCT05137054
Recruiting
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1 · Spain, France, Greece, Israel, Netherlands, United States · 41 sites
Registry update: 5 Nov 2026
NCT05469893
Recruiting
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Phase 2 · United States · 3 sites
Registry update: 16 Jul 2026
NCT05299424
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · China · 1 site
Registry update: 15 Oct 2024
NCT05444348
Recruiting
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
Not applicable · Denmark · 7 sites
Registry update: 12 Aug 2026
NCT05208307
Recruiting
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Phase 2 · United States · 1 site
Registry update: 3 Sept 2026
NCT05632380
Recruiting
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Phase 1/2 · China · 1 site
Registry update: 7 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.